As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:
20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -270 -270 |
86%
86%
|
|
| EBIT (Operating Income) EBIT | -270 -270 |
86%
86%
|
|
| Net Profit | -252 -252 |
87%
87%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Marshall Fordyce |
| Employees | 192 |
| Founded | 2016 |
| Website | veratx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


